Evidence map›Paper›PMID 25232954›Full record

ArticlePLoS neglected tropical diseases2014

Repurposed automated handheld counter as a point-of-care tool to identify individuals 'at risk' of serious post-ivermectin encephalopathy.

Sasisekhar Bennuru, Sébastien D S Pion, Joseph Kamgno, Samuel Wanji, Thomas B Nutman

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sasisekhar BennuruNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Sébastien D S PionUMI 233, Institut de Recherche pour le Développement (IRD) and University of Montpellier, Montpellier, France; Center for Research on Filariasis and other Tropical Diseases, Yaoundé, Cameroon.
Joseph KamgnoCenter for Research on Filariasis and other Tropical Diseases, Yaoundé, Cameroon; Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Yaoundé, Cameroon.
Samuel WanjiResearch Foundation in Tropical Diseases and the Environment, Buea, Cameroon; Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon.
Thomas B NutmanNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

Funding

Clinical And Therapeutic Studies Of Human Filariasis and Related DiseasesZIAAI000439 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI NUTMAN, THOMAS · 2009 to 2025
$14.8M
Intramural NIH HHS
6 · The paper itself

Abstract

introductionAdministration of ivermectin (IVM) as part of mass drug administration (MDA) campaigns for onchocerciasis and/or lymphatic filariasis (LF) has been suspended in areas co-endemic for Loa loa due to severe post-treatment adverse events (SAEs) associated with high-burden of infection (>30,000 mf/ml). One simple approach for preventing SAEs is to identify and exclude individuals at risk from MDA. Here, we describe a repurposed hand-held automated cell counter (Scepter 2.0; HHAC) as a rapid, point-of-care method for quantifying microfilariae (mf) in the blood of infected individuals. METHODOLOGY/PRINCIPAL

findingsThe quantification of microfilarial levels in blood of naturally infected humans, experimentally infected baboons, or mf-spiked human blood was tested using a microfluidic-based automated counter and compared to traditional calibrated thick-smears. We demonstrate that mf can be quantified in 20 µl of whole blood following lysis with 10% saponin within a minute of obtaining blood. There was a highly significant concordance between the counts obtained by the HHAC and those by microscopy for mf densities of >5,000 (p<0.0001, r(c) = 0.97) or >30,000 per ml (p<0.0001, r(c) = 0.90). Preliminary proof of concept field studies in Cameroon with 20 µl of blood from L. loa infected humans (n = 22) and baboons (n = 4) also demonstrated a significantly high concordance (p<0.0001, r(c) = 0.89) with calibrated thick blood smears counts. CONCLUSIONS/SIGNIFICANCE: A repurposed HHAC is a portable, sensitive, rapid, point-of-care and quantitative tool to identify individuals with high levels of L. loa mf that put them at risk for SAEs following MDA. In addition, it provides ease of data storage and accessibility.

Indexed as

Point-of-Care SystemsAnimalsAntiparasitic AgentsBrain DiseasesCameroonCell CountHumansIvermectinLoaLoiasisMaleMalondialdehydeMicrofilariaePapioAntiparasitic AgentsIvermectinMalondialdehyde

Identifiers

PMID25232954
PMCPMC4169247

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.